Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study

Overview of attention for article published in Lancet Oncology, February 2012

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 136 Dimensions

Readers on

mendeley: 112 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 136 publications that cite this research output.

136

The most recent citing publications are shown below. View all 136 publications that cite this research output on Dimensions.

Increased Blood Draws for Ultrasensitive ctDNA and CTCs Detection in Early Breast Cancer Patients

Preprint in Research Square (November 2023)

Trastuzumab Combined With Ramucirumab and Paclitaxel in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2–Positive Advanced Gastric or Gastroesophageal Junction Cancer

Article in Journal of Clinical Oncology (June 2023)

Radiothérapie et thérapie ciblée pour la prise en charge du cancer du sein : mise au point

Article in Cancer/Radiothérapie (May 2023)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.